• 1. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 2. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 3. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 4. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 5. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084

Introduction to 2-(3-Ethoxy-4-methoxyphenyl)ethyl-1,1,2,2-d4-amine HCl (CAS No. 1398066-01-7)

2-(3-Ethoxy-4-methoxyphenyl)ethyl-1,1,2,2-d4-amine HCl is a specialized chemical compound that has garnered significant attention in the field of pharmaceutical research due to its unique structural and functional properties. This compound, identified by its CAS number 1398066-01-7, belongs to a class of molecules that exhibit promising biological activities, making it a valuable candidate for further investigation in drug discovery and development. The presence of deuterium-labeled atoms (1D) in its molecular structure enhances its suitability for metabolic studies and mechanistic investigations, providing researchers with a powerful tool to elucidate its pharmacological effects.

The molecular framework of 2-(3-Ethoxy-4-methoxyphenyl)ethyl-1,1,2,2-d4-amine HCl consists of an aromatic ring substituted with ethoxy and methoxy groups, which are known to modulate the electronic and steric properties of the molecule. These substituents contribute to its interactions with biological targets, potentially influencing its binding affinity and selectivity. The deuterium labeling at the 1,1,2,2 positions serves as a stable isotope marker, enabling researchers to trace the compound's metabolism and interaction pathways with high precision. This feature is particularly useful in studying drug-drug interactions and understanding the metabolic fate of the compound in vivo.

In recent years, there has been growing interest in the development of deuterium-labeled pharmaceuticals due to their potential advantages over their non-deuterated counterparts. Deuterium substitution can lead to improved metabolic stability, reduced susceptibility to degradation by enzymes, and enhanced bioavailability. These properties make deuterated drugs attractive candidates for treating various diseases, including cancer and neurological disorders. The compound 2-(3-Ethoxy-4-methoxyphenyl)ethyl-1,1,2,2-d4-amine HCl exemplifies this trend, as it combines a structurally complex moiety with a stable deuterium label, offering a versatile platform for medicinal chemistry exploration.

Current research in the field of pharmaceutical chemistry highlights the importance of structure-activity relationships (SAR) in optimizing drug candidates. The aromatic ring system in 2-(3-Ethoxy-4-methoxyphenyl)ethyl-1,1,2,2-d4-amine HCl provides multiple binding sites that can be fine-tuned to enhance interactions with biological targets. Studies have shown that modifications in the ethoxy and methoxy positions can significantly alter the pharmacokinetic and pharmacodynamic profiles of related compounds. This underscores the need for detailed structural analysis and molecular modeling to predict and refine the biological activity of such molecules.

The synthesis of 2-(3-Ethoxy-4-methoxyphenyl)ethyl-1,1,2,2-d4-amine HCl presents unique challenges due to its complex architecture and the requirement for precise deuterium incorporation. Advanced synthetic methodologies are employed to ensure high yield and purity while maintaining the integrity of the deuterated atoms. Techniques such as deuterium exchange reactions and catalytic hydrogenation are commonly used in these processes. The successful synthesis of this compound demonstrates the growing capability in producing specialized molecules for research purposes.

Applications of 2-(3-Ethoxy-4-methoxyphenyl)ethyl-1,1,2,2-d4-amine HCl extend beyond basic research into drug discovery. Its structural features make it a potential intermediate in the synthesis of more complex pharmaceuticals. Additionally, its deuterium-labeled nature allows for detailed studies on enzyme kinetics and metabolic pathways using advanced analytical techniques such as mass spectrometry and nuclear magnetic resonance (NMR) spectroscopy. These studies can provide critical insights into how the compound interacts with biological systems and how it is processed within the body.

The use of deuterium-labeled compounds in clinical trials is also gaining traction as a means to improve drug efficacy and reduce side effects. By stabilizing metabolic pathways or altering enzyme kinetics through deuterium substitution, pharmaceuticals can achieve longer-lasting effects or higher selectivity against disease-causing targets. The potential benefits of this approach are being explored in various therapeutic areas, including oncology, where targeted therapies require precise control over drug action.

In conclusion, 2-(3-Ethoxy-4-methoxyphenyl)ethyl-1, 1, 2, 2-d4-amine HCl (CAS No. 1398066-01-)7) represents a significant advancement in pharmaceutical research due to its unique structural features and potential applications. Its combination of an intricate aromatic system with stable deuterium labeling makes it a valuable tool for studying drug metabolism, mechanism-of-action, and structure-function relationships. As research continues to uncover new possibilities in medicinal chemistry, this compound is poised to play a crucial role in developing next-generation therapeutics.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)